A GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management.
Hidradenitis suppurativa (HS) is an inflammatory skin disorder presenting with painful and draining nodules in intertriginous areas that may progress to sinus tracts. There is an increased prevalence of obesity in HS, and obesity may predispose patie…
Obesity is a chronic disease associated with increased risk of obesity-related complications and mortality. Our better understanding of the weight regulation mechanisms and the role of gut-brain axis on appetite has led to the development of safe and…
INTRODUCTION: Quantification of amyloid plaques (A), neurofibrillary tangles (T), and neurodegeneration (N) using PET and MRI is critical for Alzheimer's disease (AD) diagnosis and prognosis. Existing pipelines face limitations regarding processing t…
OBJECTIVES: To map and categorize evidence related to cardiometabolic disease (CMD) risk in persons with spinal cord injury/disease (SCI/D) and to assess the proportion of studies reporting on sociodemographic variables. DATA SOURCES: A scoping revie…
INTRODUCTION: While glucagon-like peptides 1 receptor agonists (GLP-1RAs) grow in popularity, their potential for presurgical weight optimization in spine surgery remains unclear. We examined the influence of semaglutide prescription on one- to three…
Glucagon-like peptide 1 receptor (GLP-1) agonists have been traditionally used in the treatment of type II diabetes. However, in recent times they have become a cornerstone in the pharmacological management of weight loss, and their use is increasing…
The development of novel sophisticated medications that induce weight loss has revolutionized the management of people living with obesity (PwO). However, when body weight is reduced, muscle and bone are lost along with fat. In the present review, we…
OBJECTIVES: The objective of this study was to estimate comprehensive value of semaglutide in the Medicare population for current and future FDA-approved indications. METHODS: We used data from government reports, published clinical studies, and real…
AIM: To evaluate the efficacy and safety of semaglutide 2.4 mg versus placebo for weight management in a population of Chinese adults with overweight or obesity. MATERIALS AND METHODS: In STEP 7 (NCT04251156), a double-blind, phase 3a trial, adults f…
BACKGROUND: GLP-1 receptor agonists (GLP-1RAs) are increasingly prescribed for diabetes and obesity management. Recent pharmacovigilance reports have raised concerns about potential neuropsychiatric adverse events, yet comprehensive safety assessment…
Patients with obesity-driven heart failure with preserved ejection fraction (HFpEF) often suffer from symptoms despite guideline-recommended treatment with diuretics, sodium glucose cotransporter 2 (SGLT2) inhibition, and mineralocorticoid antagonist…
Conjugating two fatty acids (2FAs) to peptide drugs can improve pharmacokinetics and therapeutic effects. However, optimizing FA spacing, chain combination, and attachment site to simultaneously enhance albumin binding and drug efficacy remains chall…
Recent evidence suggests that Glucagon-Like Peptide-1 receptor agonists (GLP-1RAs) can assist in alcohol and related substance use disorders (ASUD). GLP-1RAs act on the same receptor targets as native GLP-1, but last from several hours to a week, com…
BACKGROUND AND STUDY AIMS: We investigated the effect of semaglutide, a glucagon-like peptide-1 (GLP-1) agonist therapy, on retained gastric contents during endoscopy through a retrospective case-control study. PATIENTS AND METHODS: We performed a re…
The use of the GLP-1R agonist semaglutide is revolutionizing the treatment of obesity, yet its mechanistic effects on energy balance remain elusive. Here, we demonstrate that reactivation of semaglutide-responsive dorsal vagal complex neurons mimics…
BACKGROUND CONTEXT: Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has shown efficacy in managing glycemic control and obesity but its effects on surgical outcomes, particularly in posterior cervical fusion (PCF), are underexplored.…
BACKGROUND: Glucagon-like peptide-1 receptor agonists and their analogues have emerged as effective pharmacotherapies for obesity. OBJECTIVE: To assess the short-term cost-effectiveness of subcutaneous tirzepatide, semaglutide, liraglutide, and oral…